Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy a case series and review of the literature. brain anoxia

Summary of acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature.

Acute hyperammonemic encephalopathy induced by fluoropyrimidines (fps) is a rare complication. Its pathophysiology remains unclear, especially given the currently used regimens, including intermediate-doses of 5-fluorouracil (5-FU) or oral FP agents. We aimed to characterize the clinical manifestations in cancer patients who developed hyperammonemic encephalopathy after receiving FP-based chemotherapy.We retrospectively reviewed 1786 patients with gastrointestinal or primary-unknown cancer who received FP-based regimens between 2007 and 2012.


Eleven patients (0.6%) developed acute hyperammonemic encephalopathy.Brain anoxia the incidence according to the administered anticancer drugs were as follows: 5-FU (8 of 1176, 0.7%), S-1 (1 of 679, 0.1%), capecitabine (2 of 225, 0.9%), and tegafur-uracil (UFT) (0 of 39, 0%). Ten patients (90.9%) had at least 1 aggravating factor, including infection, dehydration, constipation, renal dysfunction, and muscle loss. All the 10 patients met the definition of sarcopenia. Median time to the onset of hyperammonemic encephalopathy in the cycle was 3 days (range: 2-21). Three patients (27.3%) developed encephalopathy during the first cycle of the regimen and the remaining 8 patients during the second or more cycles. Seven patients (63.6%) had received at least 1 other FP-containing regimen before without episodes of encephalopathy.All patients recovered soon after immediate discontinuation of chemotherapy and supportive therapies, such as hydration, infusion of branched-chain amino acids, and oral lactulose intake, with a median time to recovery of 2 days (range: 1-7).Brain anoxia four patients (36.4%) received FP-based regimens after improvement of symptoms; 3 patients were successfully managed with dose reduction, and 1 patient, who had developed encephalopathy due to S-1 monotherapy, received modified FOLFOX-6 therapy without encephalopathy later.FP-associated acute hyperammonemic encephalopathy is extremely rare, but a possible event at any time and even during the administration of oral FP agents. Particular attention is warranted when giving FP-based therapy for patients with aggravating factors, such as sarcopenia. This complication can be properly managed with early detection. Affiliation

Journal details

This article was published in the following journal.

Name: medicine ISSN: 1536-5964 pages: e6874 links

brain anoxia

• pubmed source: http://www.Ncbi.Nlm.Nih.Gov/pubmed/28562536

• DOI: http://dx.Doi.Org/10.1097/MD.0000000000006874

PubMed articles

[ 27728 associated pubmed articles listed on bioportfolio]

Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer.

Survival from gastric cancer remains poor, particularly in western populations. Previous pre-clinical and subgroup analyses of clinical trials have suggested differing benefits from fluoropyrimidine-b…

Fluoropyrimidine-associated toxicity in two gastrointestinal cancer patients: potential role of common DPYD polymorphisms.

While the majority of patients can be treated safely with fluoropyrimidine, some experience severe fluoropyrimidine-associated toxicity.Brain anoxia the frequency and severity of these adverse events vary from pa…

Valproate-induced hyperammonemic encephalopathy in a general hospital.

Chemotherapy induced stroke mimic: 5-fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy.

Stroke mimics, especially those involving chemotherapy related neurotoxicity, can confound the clinical diagnosis of acute stroke. Here we describe the case of a 63year-old male with a recent history …

Posterior reversible encephalopathy syndrome on 18F-FDG PET/CT in a pediatric patient with burkitt’s lymphoma.

We present a case of posterior reversible encephalopathy syndrome (PRES) in a pediatric patient with burkitt’s lymphoma predominantly involving the bone marrow.Brain anoxia F-FDG PET/CT scan obtained after the fi…

Clinical trials

[ 7870 associated clinical trials listed on bioportfolio]

Efficacy of L-ornithine-L-aspartate in acute hepatic encephalopathy

Hepatic encephalopathy is caused by the effects on the brain of substances that under normal

Circumstances are efficiently metabolized in the liver. The hyperammonemia is the main

Factor r…

Efficacy of albumin for acute encephalopathy in patients with cirrhosis

The purpose of this study is to determine whether the administration of albumin in addition

To the standard care is effective in the treatment of an episode of hepatic encephalopathy

In pa…

Pathogenesis and cerebrovascular manifestations of septic encephalopathy

brain anoxia

Septic encephalopathy is an important complication of sepsis. Why some patients with sepsis

Develop septic encephalopathy is unknown. We will investigate whether patients who develop

This …

Lactulose for the prevention of hepatic encephalopathy in cirrhotic patients with upper gastrointestinal hemorrhage

To evaluate the role of lactulose in prevention of clinically overt hepatic encephalopathy

(HE) in the setting of acute upper gastrointestinal bleeding in cirrhotic patients

Heart beat variability in neonatal encephalopathy

This study will find out if analysing heartbeat in babies with brain injury, based on

Standard clinical monitors, can inform treatment decisions and monitor stress levels in real

brain anoxia

Time

Acute febrile encephalopathy

Acute onset of fever accompanied by seizures, cerebral inflammation and a change in mental status (e.G., confusion, disorientation, and coma).

Consolidation chemotherapy

Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.

Maintenance chemotherapy

Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.

Arsenic poisoning

Disorders associated with acute or chronic exposure to compounds containing ARSENIC (ARSENICALS) which may be fatal.Brain anoxia acute oral ingestion is associated with gastrointestinal symptoms and an encephalopathy which may manifest as SEIZURES, mental status changes, and COMA. Chronic exposure is associated with mucosal irritation, desquamating rash, myalgias, peripheral neuropathy, and white transverse (mees) lines in the fingernails. (adams et al., principles of neurology, 6th ed, p1212)

Induction chemotherapy

Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.